--Merck Capital Joins Flagship Ventures Backing Leader in Fluorescence In
WOBURN, Mass., Oct. 23 /PRNewswire/ -- VisEn Medical, Inc., a leader in fluorescence in vivo imaging from research through medicine, today announced the completion of its Series B financing. Merck Capital Ventures joined Flagship Ventures to co-lead this $7 million investment round, which also included The Bollard Group and other existing investors. Per Lofberg, President and Chief Executive Officer of Merck Capital Ventures will join VisEn Medical's board of directors.
"I am pleased to have Merck Capital join Flagship Ventures in supporting our company," said Kirtland Poss, President and Chief Executive Officer of VisEn Medical. "We intend to use the proceeds of the Series B financing to expand our sales, marketing and customer support programs, launch additional new products from our technology platforms, and further advance the development of our technologies in clinical imaging applications."
"We look for companies with strong management and proven technology platforms," said Mr. Lofberg of Merck Capital Ventures. "VisEn Medical exemplifies these qualities and has already established a clear leadership position in fluorescence in vivo imaging, a field of growing importance in the pharmaceutical and healthcare industries."
Ed Kania, Chairman of VisEn Medical and Managing Partner of Flagship Ventures noted, "We see tremendous value and promise in VisEn's leading position and close working relationships with top pharmaceutical companies in fluorescence in vivo imaging. We are very pleased to continue our strong support and participation with VisEn in this groundbreaking area."
About VisEn Medical, Inc.
VisEn Medical, Inc. was founded in 2000 based on fluorescence in vivo imaging technologies initially developed by industry-leading researchers and clinicians at the Massachusetts General Hospital and Harvard Medical School. VisEn develops and commercializes the industry's highest performing fluorescence in vivo imaging technology platforms, from research through medicine. The Company also works directly with large pharmaceutical partners to design ranges of tailored molecular imaging probes and applications that are targeted to their specific research areas. Privately-held VisEn is headquartered in Woburn, Massachusetts and has been financed by leading venture firms including Flagship Ventures, Merck Capital Ventures and The Bollard Group. For further information please visit http://www.visenmedical.com.
About Merck Capital Ventures, LLC
Merck Capital Ventures is a subsidiary of Merck & Co., Inc. founded in November 2000. Merck Capital Ventures (MCV) actively invests in emerging businesses with interesting technology in areas related to the commercialization, distribution and delivery of pharmaceuticals and related healthcare services. The focus of MCV is to invest in technologies that accelerate innovation related to the pharmaceutical business and other sectors of health care delivery. For further information, see http://www.merckcapitalventures.com.
About Flagship Ventures
Flagship Ventures is a leading venture capital firm focused on creating, financing, and building innovative companies. Founded in 2000, Flagship operates from its offices at Kendall Square in Cambridge, MA. With an active portfolio of over 40 companies, the firm's strategy is to balance its investments across three principal business sectors: Life Science / Diagnostics Tools, Energy & Technology Platforms, and Therapeutics. Through its unique venture creation and seed investing programs, Flagship actively participates in developing new ventures that are commercializing many of the leading breakthroughs of our times. For more information, visit http://www.flagshipventures.com.
|SOURCE VisEn Medical, Inc.|
Copyright©2007 PR Newswire.
All rights reserved